Eris Lifesciences has launched DEMELAN NEXA Serum, targeting evolving needs in pigmentation and melasma management. The formulation reflects growing scientific understanding of pigmentation biology and treatment pathways. It aims to support dermatologists with a more comprehensive approach to recurrent melasma and photoaging. Addressing gaps in current treatments Melasma remains a persistent challenge in dermatology, with high recurrence rates reported in ...
The global micropigmentation market is valued at US$ 102.16 million in 2024. It is projected to reach US$ 202.02 million by 2033, growing at a CAGR of 7.87 per cent from 2025 to 2033. This growth is fuelled by changing beauty standards, rising disposable incomes, and digital media influence. As more people seek low-maintenance, long-lasting cosmetic solutions, micropigmentation has gained ...
Artificial intelligence (AI) continues to revolutionise healthcare, and dermatology is evolving with it. Recent data values the AI-powered drug discovery market in dermatology at USD 234.7 million in 2024. Experts project it will grow to USD 1,924.6 million by 2034, fuelled by a strong CAGR of 24.2 per cent from 2025 to 2034. Transforming dermatology with AI AI-driven drug discovery ...
Galderma showcased significant updates across its dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting. The company reinforces its leadership commitment in dermatology innovation with 22 scientific presentations, including two oral e-posters. Nemluvio Nemolizumab (Nemulizumab), Galderma’s treatment for prurigo nodularis and atopic dermatitis, was a key focus at AAD 2025. A new oral presentation showcases Nemluvio’s efficacy ...